Philippines Diabetes Drugs Market Analysis Sample report

1. A sample report on Philippines Diabetes Drugs Market Analysis Includes Market Size, Market Segmented by Types and Key Competitors (Data forecasts from 2022 – 2030F) www.insights10.com

2. This report presents a strategic analysis of the Philippines Diabetes Drugs Market Analysis and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Philippines Diabetes Drugs Market Analysis, and offers unmatched value, accuracy, and expert insights

3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

4. Table of Content CONTENT PG. NO. 12-25 1. Philippines Diabetes Drugs Market Overview 1.1. Overview 1.2. Philippines Overview 1.3. Economic Overview: Philippines 1.4. Philippines Diabetes Drugs Market Market in Philippines 1.5. Pharmaceuticals Market in Philippines 1.6. Healthcare Scenario in Philippines 1.7. Health Insurance Coverage: Philippines 1.8. Budget of the Government for Public Insurance 1.9. Mergers and Acquisitions 26-30 2. Market Size and Forecasting 2.1 Market size and forecasts (Excel and Methodology) 4 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

5. Table of Content CONTENT PG. NO. 2.2. Market Segmentation 2.2.1. By Drug 2.2.2. By Applications 2.2.3. By Distribution Channel 31-34 3. Market Dynamics 3.1. Market Growth Drivers 3.1.1. Philippines Diabetes Drugs Market Analysis Driver 1 3.1.2. Philippines Diabetes Drugs Market Analysis Driver 2 3.1.3. Philippines Diabetes Drugs Market Analysis Driver 3 3.2. Market Restraints 3.2.1. Philippines Diabetes Drugs Market Analysis Restraint 1 3.2.2. Philippines Diabetes Drugs Market Analysis Restraint 2 5 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

6. Table of Content CONTENT PG. NO. 3.2.3. Philippines Diabetes Drugs Market Analysis Restraint 3 35-45 4. Competitive Landscape 4.1. Major Market Share 4.2. Key Company Profile 4.2.1. AC Health 4.2.1.1. Overview 4.2.1.2. Product Applications & Services 4.2.1.3. Recent Developments 4.2.1.4. Partnerships Ecosystem 4.2.1.5. Financials (Based on Availability) 4.2.2. Eli Lilly 4.2.2.1. Overview 6 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

7. Table of Content CONTENT PG. NO. 4.2.2.2. Product Applications & Services 4.2.2.3. Recent Developments 4.2.2.4. Partnerships Ecosystem 4.2.2.5. Financials (Based on Availability) 4.2.3. Boehringer Ingelhein 4.2.3.1. Overview 4.2.3.2. Product Applications & Services 4.2.3.3. Recent Developments 4.2.3.4. Partnerships Ecosystem 4.2.3.5. Financials (Based on Availability) 4.2.4. Astrezeneca 4.2.4.1. Overview 7 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

8. Table of Content CONTENT PG. NO. 4.2.4.2. Product Applications & Services 4.2.4.3. Recent Developments 4.2.4.4. Partnerships Ecosystem 4.2.4.5. Financials (Based on Availability) 4.2.5. Sanofi 4.2.5.1. Overview 4.2.5.2. Product Applications & Services 4.2.5.3. Recent Developments 4.2.5.4. Partnerships Ecosystem 4.2.5.5. Financials (Based on Availability) 4.2.6. Novartis 4.2.6.1. Overview 8 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

9. Table of Content CONTENT PG. NO. 4.2.6.2. Product Applications & Services 4.2.6.3. Recent Developments 4.2.6.4. Partnerships Ecosystem 4.2.6.5. Financials (Based on Availability) 4.2.7. Takeda Pharmaceuticals 4.2.7.1. Overview 4.2.7.2. Product Applications & Services 4.2.7.3. Recent Developments 4.2.7.4. Partnerships Ecosystem 4.2.7.5. Financials (Based on Availability) 4.2.8. Johnson and Johnson 4.2.8.1. Overview 9 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

10. Table of Content CONTENT PG. NO. 4.2.8.2. Product Applications & Services 4.2.8.3. Recent Developments 4.2.8.4. Partnerships Ecosystem 4.2.8.5. Financials (Based on Availability) 4.2.9. Bayers AG 4.2.9.1. Overview 4.2.9.2. Product Applications & Services 4.2.9.3. Recent Developments 4.2.9.4. Partnerships Ecosystem 4.2.9.5. Financials (Based on Availability) 4.2.10. Novonordisk 4.2.10.1. Overview 10 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

11. Table of Content CONTENT PG. NO. 4.2.10.2. Product Applications & Services 4.2.10.3. Recent Developments 4.2.10.4. Partnerships Ecosystem 4.2.10.5. Financials (Based on Availability) 46-53 5. Reimbursement Scenario 5.1. Reimbursement Regulation 5.2. Reimbursement Process for Diagnosis 5.3. Reimbursement Process for Treatment 5.4 Reimbursement Process – Medicare 5.5 Reimbursement Process - Medicaid 54 6. Methodology & Scope 11 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

12. Philippines Diabetes Drugs Market Analysis 1. Philippines Diabetes Drugs Market Overview

13. 1.1 Statistics at a Glance: The Burden of Diabetes in the World Scope of Philippines Diabetes Drugs Market Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 537.68 Mn persons (20-79 years old) are expected to suffer diabetes worldwide in 2023. 738 Mn By 2030, there will be 643 million diabetics worldwide, and by 2045, there will be 783 million. In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ 2.59 Mn Approximately 2.59 Mn people are dying from diabetes in 2022. globally 48% In 2021, 48% of all deaths due to diabetes occurred before the age of 70 years In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 13 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

14. 1.1 Statistics at a Glance: The Burden of Philippines Diabetes Drugs Market in the World (continued) Europe ~Revenue to reach $xx Bn by 2027 North America ~ Market Size of $xx Bn Asia -Fastest CAGR Africa Egypt Market ~$xx Market ~Market Size of $xx Illustrative Illustrative 14 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

15. 1.2 Philippines Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 113.9 Mn Is the population of Philippines, in 2022 394.08 Bn Is the Gross Domestic Product (GDP) in Philippines in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 24.5 Is the median age in Philippines, in 2022 $9.25 k per capita was the amount of national health expenditures in 2021 15 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

16. 1.3 Economic Overview: Philippines Population of Philippines, (2020-2030) GDP of Philippines, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 Male 49% Female 51% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 55-64 65+ Illustrative Illustrative 16 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

17. 1.4 Statistics at a Glance: The Burden of Diabetes in Philippines Scope of Philippines Diabetes Drugs Market Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 5.67 Mn In the Philippines, diabetes has been identified in more than 5.67 million persons by 2021. 7.1% Diabetes prevalence (% of population ages 20 to 79) in Philippines was reported at 7.1 % in 2021 In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in Philippines ▪ 41.68 Mn Insulin is used by more than 41.68 Mn people in the Philippines, including 100% of those with Type 1 diabetes and 10% to 25% of those with Type 2 diabetes. 32.45% More than 32.45% of Diabetes patient with type 2 diabetes have cardiovascular complications, while more than 87 percent are either overweight or obese In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 17 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

18. 1.5 Pharmaceuticals in Philippines Philippines Pharmaceuticals Market Forecast, 2022-2030 (in $Bn) xx xx xx xx xx xx xx xx xx 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Pharmaceuticals market in Philippines, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 18 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

19. 1.6 Healthcare Scenario in Philippines Diabetes Drug Drug Development Process: The process of developing a Diabetes Drug drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the Diabetes Drug drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating Diabetes Drug Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market o o o o o FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means FDA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 19 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

20. 1.6 Healthcare Scenario: SCD Patient Journey Presentation Diagnosis Treatment Follow up Confirmatory Diagnosis Complete blood count (evaluate number & quality of RBCs, Hb & WBCs) Prevention and management of crisis: • For VOC and Splenic Sequestration: HU, Endari, Adakveo, Oxbryta • For infections: Antibiotics, Vaccines • Long term follow-up is required for patients with SCD • Annual assessment: CBC and reticulocyte count, iron status, liver and renal function tests, urinalysis, LDH, vitamin D level and neurocognitive assessment • ESOD (End Stage Organ Damage) evaluation starting from age 7 • Yearly Transcranial Doppler test to determine risk of stroke Initial Diagnosis Imaging (confirm bone related changes or respiratory problems) A suspected diagnosis is usually made, based on physical examination and detailed patient and family history Prenatal screening/ Neonatal screening Bacterial cultures of blood, sputum, urine, stool (detect any infection) Prevention and management of complications: Genetic testing (detect the type of SCD) • Stroke: Chronic transfusions, HU Stakeholders PCP, pediatrician, neonatologist, endocrinologist, cardiologist, hematologist, orthopedist, psychologist and psychiatrist PCP, paediatrician, neonatologist, haematologist and genetic counsellor PCP, pediatrician, medical geneticist, cardiologist, hematologist, endocrinologist, psychologist and psychiatrist PCP, pediatrician, medical geneticist, hematologist, gynecologist and pathologist Depending on the organ complications, the treatment involves different specialists at different times Illustrative Illustrative 20 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

21. 1.7 Health Insurance Coverage: Philippines % of People by Type of Health Insurance Coverage (2021) Number of People By Health Insurance Coverage Coverage Type 2020 2021 Change % 8.3 Uninsured Total 327,521 328,074 91.7 With health insurance Any health plan 299,230 300,887 0.4 Any private plan 217,896 216,366 –0.6 66.0 Any private plan Employment-based 178,737 178,285 –0.2 54.3 Employment-based Direct-purchase 33,869 33,555 –0.1 10.2 Direct-purchase Marketplace coverage 10,924 11,389 0.1 3.5 Marketplace TRICARE 9,165 8,299 –0.3 2.5 TRICARE Any public plan 112,925 117,095 1.2 Medicare 58,541 60,226 0.5 35.7 Any public plan 18.4 Medicare Medicaid 58,778 61,940 0.9 18.9 Medicaid VA and CHAMPVA 2,967 3,151 0.1 1.0 VA and CHAMPVA Uninsured 28,291 27,187 –0.4 In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire calendar year More people had private health insurance (66%) than public coverage (35.7%) Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%), followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%) ▪ ▪ ▪ Illustrative Illustrative 21 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

22. 1.8 Budget of Philippines Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Medicare In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Medicaid 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Medicare As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Medicaid National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% oftotal NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 22 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

23. 1.9 Mergers and Acquisitions RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend $16.7 112 110 107 107 89 82 $11.7 $10.5 $7.7 $6.8 $6.0 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 Buyer Composition: Strategic Vs Financial (2020) Buyer Type by Deal Size ($Mn) 39% 41% 41% 42% 58% 59% 59% 61% Strategic Buyers Financial Buyers $0- $25 $25-$50 $50-$100 $100+ 57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020 Illustrative Illustrative 23 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

24. 1.9 Mergers and Acquisitions (continued) Latest Deals In Philippines Amount / Duration Company Name Type Year Key Pointers Oracle’s acquisition of Cerner is big tech’s latest foray into the healthcare system, promising better outcomes Oracle acquire Cerner through an all-cash tender offer for $95.00 per share, or approximately $28.3 Bn in equity value Cerner is a leading provider of digital information systems used within hospitals and health systems to enable medical professionals to deliver better healthcare to individual patients and communities ▪ ▪ Acquisition $28.3 Bn June, 2022 ▪ Oracle acquisition of Cerner GSK has acquire BELLUS for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion ▪ BELLUS is a late-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough ▪ Acquisition $2 Bn April 2023 Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough ▪ GSK acquisition of BELLUS Health Illustrative Illustrative 24 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

25. 1.9 Mergers and Acquisitions (continued) Latest Deals In Philippines Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 Illustrative Illustrative 25 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

26. Philippines Diabetes Drugs Market Analysis 2. Market Size and Forecasting

27. 2.1 Market size and forecasts (Excel and Methodology) Click on the icon to know the methodology and assumption Philippines Diabetes Drug Market Forecast, 2022-2030 (in $Bn) Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX XX In this section you will get an understanding of the overall Healthcare Insurance market in Malaysia, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2025 2027F 2026 2028F 2027 2029F 2030F 2023 2024 2028 2029 2030 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Major Markets Patient (Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Philippines Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ % of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Philippines Market Size (Bn $) 61 74 84 87 91 95 99 106 27 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

28. 2.2 Snapshot of Philippines Diabetes Drug Market Segmentation By Distribution Channel By Application By Drug Hospital Pharmacy Injectable Drugs Type 1 Diabetes Retail Pharmacy Oral Drugs Type 2 Diabetes Online Pharmacy Other In this section you will get an understanding of the segmentations which will cover the Philippines Diabetes Drugs Market Analysis ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 28 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

29. 2.2.1 Market Segmentation: By Drug Type Philippines Diabetes Drug Market Share, By Drug Type (2022) Injectable drugs market in Philippines is a significant component of the overall Diabetes Drug treatment market ▪ It has the maximum market share in Philippines Diabetes Drug market with approximately xx% ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Oral Drugs, 15% Injectable Drugs, 20% In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 29 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

30. 2.2.2 Market Segmentation: By Application Philippines Diabetes Drug Market Share, By Application (2022) Type 1 drug market in Philippines is a significant component of the overall Diabetes Drug market ▪ It has the maximum market share in Philippines Diabetes Drug market with approximately xx% ▪ Type 2, 20% Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Type1, 38% Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 30 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

31. 2.2.3 Market Segmentation: By Distribution Channel Philippines Diabetes Drug Market Share, By Distribution Channel (2022) Hospitals have the maximum market share in Philippines Diabetes Drug market with approximately xx% ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Online Pharmacy In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Hospital Pharmacy Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Retail Pharmacy 31 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

32. Philippines Diabetes Drugs Market Analysis 3. Market Dynamics

33. 3.1 Market growth drivers 3.1.1 Incidence of Diabetes is increasing in Philippines, with more than 5.6 Mn new Diabetes cases expected to be diagnosed in 2023 Incidence of Diabetes is increasing in Philippines, with more than 5.6 Mn new Diabetes Drug cases expected to be diagnosed in 2023 ▪ Incidence of Diabetes in Philippines This is driving the demand for Diabetes Drug treatments and creating opportunities for growth in the Diabetes Drug market ▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 2010 2022 2030 Illustrative Illustrative 33 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

34. 3.1 Market growth drivers (continued) 3.1.2 Death rate from Diabetes Drug in Philippines has declined by 42.58% from 2010 to 2022, largely due to advances in technology and treatment options Top countries that are leveraging technology in their fight against Diabetes Drug Philippines has a long history of investing in Diabetes Drug research and treatment, and as a result, has become a world leader in the field ▪ Norway IT has a robust healthcare infrastructure, including world- renowned research institutions, hospitals, and clinics, that are dedicated to Diabetes Drug treatment and research ▪ Austria Denmark Belgium Spain One of the key factors that has allowed Philippines to stay ahead in the field of Diabetes Drug research and treatment is the high level of investment in Diabetes Drug-related research ▪ Italy Netherlands Sweden Singapore Switzerland Israel In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Australia Canada France Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ United Kingdom China South Korea Germany Japan United States Illustrative Illustrative 34 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

35. 3.2 Market restraints 3.2.1 In 2021, the average cost of a new Diabetes Drug drug was over $985.65 per year 3.2.2 Average cost of developing a new Diabetes Drug drug that is ultimately approved by the Philippines FDA is over $1465.67 Mn 3.2.3 Demand for Diabetes Drug care is expected to increase by 61.58% by 2025, while the supply of oncologists is only expected to increase by 38.42% Diabetes Drug treatments can be very expensive and can lead to financial burden for patients and healthcare systems Regulatory requirements for Diabetes Drug treatments can be very stringent, which can slow down the approval process and limit access to new treatments Regulatory bodies, such as Philippines Food and Drug Administration (FDA), require extensive clinical trials and safety data before approving new Diabetes Drug treatments This can be a lengthy and costly process, which can delay the availability of new treatments for patients There is a shortage of oncologists in Philippines, which can limit access to Diabetes treatments and create barriers to growth in the Diabetes Drug market Oncologists are physicians who specialize in the diagnosis and treatment of Diabetes Drug With the aging population and the increasing incidence of Diabetes Drug, there is a growing demand for oncologists However, the supply of oncologists is not keeping pace with the demand Illustrative Illustrative ▪ ▪ ▪ ▪ ▪ Cost of Diabetes Drug treatment varies depending on the type of Diabetes Drug, stage of Diabetes Drug, and treatment options ▪ ▪ ▪ ▪ Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. 35 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

36. Philippines Diabetes Drugs Market Analysis 4. Competitive Landscape

37. 4.1 Major Market Share Revenue of Major players in Philippines Diabetes Drug Market ($ Mn) Philippines Diabetes Drug market is a highly competitive space, with many companies developing and marketing Diabetes Drug treatments ▪ Other Some of the top companies in Philippines Diabetes Drug market based on revenue and market share include ▪ Roche is a Swiss multinational healthcare company that develops and markets Diabetes Drug treatments, including targeted therapies and immunotherapies ▪ In 2020, Roche's oncology sales were approximately $24 Bn, making it one of the largest players in Philippines Diabetes Drug market ▪ XX Illustrative Illustrative 37 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

38. 4.2 Key Company Profile Key Note: 1 AC Health Here is the list of top 10 companies which will cover in the final report ▪ 2 Eli Lilly Each company will have slides for ▪ 3 Boehringer Ingelheim Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report o o 4 Astrazeneca o o 5 Sanofi o 6 o NovoNordisk o 7 Takeda Pharmaceuticals o 8 Novartis ▪ 9 Johnson & Johnson ▪ 10 Bayers AG 38 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

39. 4.2.1 AC Health Solutions offered by AC Health Founded in: 2015 ▪ AC Health is a pharmaceutical company that develops and produces various medications, including those used to treat Diabetes ▪ It has a significant presence in the Diabetes Drug treatment field in the Philippines ▪ Through its three pillars—pharma, hospitals and clinics, and digital health—AC Health creates a seamless and integrated healthcare ecosystem for the Filipino patient ➢ Diagnostics HQ: Manila,Philippines ➢ Pharmaceuticals Type: Private ➢ Healthcare Software Revenue: $85.658 Bn ➢ Clinical Trials Website: www.achealth.com ➢ Patient Support Recent Activity / Press Coverage AC Health Tecentriq plus Avastin reduced the risk of Diabetes Drug returning in people with certain types of adjuvant Diabetes Drug in a Phase III study AC Health launches two new Medicines to identify key clinical mutations in patients with Diabetes Healthway Philippines partners with Diabetes Philippines and AstraZeneca to fight kidney disease 39 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

40. 4.2.1 AC Health (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners One of the largest pharmaceutical distributors in the United States, McKesson has been a long-standing distribution partner for Roche Roche has been working with SAP, a leading software company, to develop digital solutions for its healthcare products A leading Swiss biotechnology company, Lonza provides Roche with contract manufacturing services for the production of its biologics and pharmaceuticals Cardinal Health is a Fortune 500 healthcare services company that provides pharmaceutical distribution services to Roche It is one of the largest drugstore chains in the United States and Europe, and its extensive network of retail locations and distribution centers make it an important distribution partner for Roche Roche has a strategic partnership with Microsoft to leverage its cloud computing and AI technologies in the development of new healthcare products Thermo Fisher Scientific is a leading provider of analytical instruments, reagents, and laboratory services A leading healthcare services provider in Asia, Zuellig Pharma is a distribution partner for Roche in several Asian countries GE Healthcare provides Roche with advanced medical imaging and diagnostics technologies, including CT scanners and MRI machines Illustrative Illustrative One of the largest pharmaceutical wholesalers in Europe, PHOENIX Group distributes Roche's products in several European countries 40 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

41. 4.2.1 AC Health (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Ayala Group's AC Health and AC Logistics join together to strengthen sustainability efforts AC Health’s hospitals and clinics group, Healthway Philippines, Inc. (HPI), and its pharmaceutical importation and distribution arm, IE Medica and MedEthix, entered into a partnership with AC Logistics’ Integrated Waste Management ▪ February, 2023 ▪ Collaboration - AC Logistics AC Health’s clinics and hospitals group, Healthway Philippines, Inc. (HPI), entered into a partnership with Diabetes Philippines Inc (DP), Philippine Association of Diabetes Educators (PADE), Association of Diabetes Nurse Educators of the Philippines (ADNEP) and AstraZeneca Philippines, to launch ACT Now, a Chronic Kidney Disease (CKD) screening program within the QualiMed hospital network and Healthway clinics ▪ Partnership - January, 2023 Astrazeneca 41 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

42. 4.2.1 AC Health (continued) Revenues ($Bn), 2020-2030 According to Roche's 2020 financial report, the company had sales of CHF 58.3 Bn (Swiss Francs) in 2020 ▪ This is equivalent to approximately $63.3 Bn USD, based on exchange rates at the end of 2020 70.9 ▪ 70.3 63.3 Company's Pharmaceuticals Division generated sales of CHF 49.9 Bn in 2020, while the Diagnostics Division generated sales of CHF 8.4 Bn ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Breakdown of Net Revenue by Segment, 2022 Revenue generated by Roche in 2020 reflects the company's continued growth and success in the healthcare industry ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 1 2 3 4 Illustrative Illustrative 42 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

43. 4.2.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Drugs for Diabetes Drug Recent Activity / Press Coverage Drugs Indications Illustrative Illustrative 43 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

44. 4.2.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners Illustrative Illustrative 44 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

45. 4.2.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Illustrative Illustrative 45 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

46. 4.2.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 46 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

47. Philippines Diabetes Drugs Market Analysis 5. Reimbursement Scenario

48. 5.1 Reimbursement Regulation Medicare and Medicaid together provide health insurance coverage for more than 4 in 10 Americans The reimbursement scenario in the US Diabetes Drug market is complex and can vary depending on the specific treatment, setting of care, and insurance coverage. Here are some key points to consider: Medicare: o ▪ Medicare is a federal health insurance program for people aged 65 and older, as well as people with certain disabilities or health conditions Medicare covers many Diabetes Drug treatments, including chemotherapy, radiation therapy, and some immunotherapies However, coverage can be subject to strict guidelines and restrictions, such as the requirement for prior authorization Medicaid: o Medicaid is a joint federal-state program that provides health insurance for people with low incomes o Medicaid coverage for Diabetes Drug treatments can vary by state, and may be subject to limits on the amount and type of treatment covered Private Insurance: o Private insurance coverage for Diabetes Drug treatments can also vary widely depending on the insurer and the specific policy o Some policies may have high out-of-pocket costs, such as deductibles and co-pays, while others may have more comprehensive coverage Other Public 1% o Other Private 3% Uninsured 9% Medicare 17% o ▪ Medicaid and CHIP 21% ▪ Employer-Sponsored 49% Health Insurance Coverage, 2022 Illustrative Illustrative 48 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

49. 5.1 Reimbursement Regulation (continued) Affordable Care Act: Affordable Care Act (ACA) includes provisions to help improve access to Diabetes Drug treatments by requiring insurers to cover certain preventive services, including Diabetes Drug screenings, without co-pays or deductibles It also includes protections for people with pre-existing conditions, such as Diabetes Drug Reimbursement for New Treatments: Reimbursement for new Diabetes Drug treatments can be a complex and lengthy process, as insurers and government programs often require evidence of safety and effectiveness before providing coverage This can create challenges for companies developing and marketing new treatments Value-Based Care: There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the value of treatments rather than simply the volume of treatments Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics ▪ o o ▪ o o ▪ o o In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative 49 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential

50. 5.1 Reimbursement Regulation (continued) Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023  Public healthcare coverage is provided by the government and includes programs like Medicare and Medicaid  Medicare is a federal program that provides healthcare coverage to individuals who are 65 years of age or older, as well as certain younger people with disabilities  Medicaid is a joint federal-state program that provides healthcare coverage to individuals with low income and limited resources 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 50 A Sample Report on Philippines Diabetes Drugs Market Analysis Analysis I Confidential